NeurAxis, Inc.

AMEX:NRXS

Biotechnology

Healthcare
$4.87 +4.25%

+$0.29 today

Market cap
$69.12M
Beta
1.41
P/E (TTM)
-10.5
EPS (TTM)
-$0.67
52W Low $2.20High $9.33

Volume 0.23M

Average 0.18M

NRXS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

NeurAxis, Inc.AMEX: NRXS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $1.39M rose 83.8% year over year, ahead of the +44.4% change in trailing-twelve-month gross profit. Sequentially, it rose 68.1% from the prior quarter. Over 3 fiscal years it compounded at +8.0% a year.

Context

  • Gross profit amounted to 84.2% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +83.8% holds above the trailing-twelve-month pace of +44.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.39M+68.1% QoQ
Last fiscal yearDec 2025
$3.01M+29.4% YoY
LTMMar 2026
$3.64M+44.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.8%——
1 year+29.4%——
3-year CAGR+8.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
3.01M USD
Year-over-year change
+29.4%
4-year CAGR
+7.5%

Gross Profit vs competitors

How NRXS compares with its peers on the latest reported figures

  • NRXS's LTM Mar 2026 gross profit of $3.64M is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +44.4% is the highest of 3, against a peer median of +24.1%.
  • Gross profit amounts to 85.0% of revenue for NRXS, versus a peer median of 99.7%.
NRXS Competitors Peer median
Gross Profit for NRXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRXSNeurAxis, Inc.LTM Mar 2026$3.64M +44.4%+8.0%85.0%
RLYBRallybio CorporationLTM Mar 2026$855K +9.1%—99.7%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025-$332K +39.1%——
Peer median (excluding NRXS) $0+24.1%—99.7%

Competitors are the stored peer set for NRXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M2.68M2.46M2.69M3.57M
Cost of Revenue467.66K297.06K303.35K362K562.92K
Gross Profit2.25M2.39M2.16M2.32M3.01M
Gross Margin82.8%88.9%87.7%86.5%84.2%
Research & Development203.41K225.61K169.32K206.11K493.61K
Selling, General & Admin5.02M5.53M8.65M9.27M10.34M
Operating Expenses5.22M5.76M8.82M9.48M10.84M
Depreciation & Amortization36.71K37.13K40.73K37.83K59.5K
EBITDA(2.95M)(4.33M)(9.23M)(7.9M)(7.67M)
EBITDA Margin-108.6%-161.1%-375.1%-294.2%-214.8%
Operating Income(2.97M)(3.37M)(6.66M)(7.16M)(7.83M)
Operating Margin-109.1%-125.6%-270.9%-266.5%-219.4%
Interest Income0(2.32M)(2.77K)00
Interest Expense36.93K417.6K5.36M300.72K73.97K
Other Income / Expenses(58K)(1.41M)(7.96M)(1.08M)29.35K
Income Before Tax(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Pre-Tax Margin-111.3%-178.0%-594.6%-306.8%-218.5%
Income Tax Expense00000
Net Income(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Net Margin-111.3%-178.0%-594.6%-306.8%-218.5%
EPS (Basic)(0.62)(0.57)(2.32)(1.22)(0.95)
EPS (Diluted)(0.62)(0.78)(2.32)(1.22)(0.95)
Weighted Avg Shares5.38M8.41M6.3M6.92M9.08M
Weighted Avg Shares (Diluted)5.38M8.41M6.3M6.92M9.08M

NeurAxis, Inc.

AMEX:NRXS

Intrinsic Alpha fair value

Locked

Current Price

$4.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.